ADOT PR on Biomoda Lung Cancer Cure is out on Business Wire
Biomoda Conducting Blind-Study of Early Detection Lung Cancer Test Through LungCheck of
Scottsdale, Arizona
Patented Technology Presents A Leading Hope for Lung Cancer Cure
ALBUQUERQUE, N.M.--(BUSINESS WIRE)--July 15, 1998--Advanced Optics Electronics, Inc.
(OTC BB: ADOT) today announced significant developments regarding Biomoda, Inc., a
biotechnology company in which Advanced Optics has approximately 27% ownership.
Biomoda, Inc. has contracted with LungCheck(R), Inc. of Scottsdale, AZ to perform a 60-patient
blind-study on Biomoda's proprietary lung cancer diagnosis technology. LungCheck is a respected
cytopathology lab chosen for their familiarity with sputum technology.
Biomoda's patented lung cancer test is capable of detecting lung cancer up to six years earlier than
any other available test. LungCheck's blind-study of Biomoda's revolutionary technology should
be completed by September.
The results of this blind-study will be presented to recognized medical journals and will provide the
third-party verification necessary for presentation to the national media.
Biomoda's technology also encompasses the treatment of lung cancer. Biomoda's prominent
research team has included world-leading cytopathologists, Dr. Geno Saccomanno of St. Mary's
Hospital and Medical Center, Dr. Jim Mulshine of the National Cancer Institute and the late Dr.
John Frost of Johns Hopkins University.
Biomoda believes this technology is a leading hope for a cure for lung cancer. FDA approval will
not be necessary for the patented non-invasive lung cancer test, but will be required for the
patented treatment process.
Biomoda, Inc. is currently in discussions with several major pharmaceutical companies regarding
this patented technology. It is anticipated that results from this latest round of studies will provide
Biomoda with the data necessary to conclude major marketing and distribution agreements with
several major partners in the United States and abroad.
This press release contains forward-looking statements with respect to the results of operations,
expectations and business of the Company that involves risk and uncertainties. The Company's
actual future results could materially differ from those discussed. Risks and uncertainties of the
Company will be detailed from time to time in the Company's periodic reports to be filed with the
Securities and Exchange Commission.
ADVANCED OPTICS COMPANY INFORMATION
Advanced Optics Electronics, Inc. (OTC Bulletin Board: ADOT - news) is a developer of patented
electronic display technology, utilizing ADOT's proprietary SLM (Spatial Light Modulator) light
valve. This industry-leading technology can be utilized in many diverse fields including the
production of "television quality" advertising billboards, medical testing equipment, military
displays, computer monitors and high definition video transmission. Advanced Optics Electronics
actively seeks partnerships with companies in fields that could benefit from ADOT's patented
technology. ADOT also owns in excess of 27% of Biomoda, Inc., an emerging biotechnology
company specializing in breakthrough cancer diagnostics and therapy. Advanced Optics
Electronics, Inc. has retained first right of refusal to design, manufacture and distribute the
necessary scanning testing devices for the lung cancer tests using Advanced Optics Electronics'
proprietary display technology.
Contact Advanced Optics Electronics, Inc. at (505) 797-7878 or visit their web site at
adot.org. |
